Buradasınız

Anasayfa » Content

Renal medüller karsinom: 3 olgunun sunumu

Renal medullary carcinoma: a report of three cases

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Renal medullary carcinoma is a very aggressive malignant epithelial tumor of the kidney. In this study, three cases of renal medullary carcinoma are presented, one of which was diagnosed by nephrectomy and the others with biopsy. Histologically, the tumors were composed of diffuse or glandular architecture accompanying neutrophilic inflammatory component. The neoplastic cells have plasmacytoid or rhabdoid appearance. Immunohistochemically, the neoplastic cells showed positivity with epithelial membrane antigen, vimentin, Cam5.2, pancytokeratin AE1/AE3 and focally cytokeratin 7 and p53, and showed negativity with Her2neu (c-erb-b2), CEA, high molecular weight cytokeratin (34ßE12) and cytokeratin 20. Two of the patients died within the first year after diagnosis. Renal medullary carcinoma is different from other renal carcinomas by histogenesis, diagnosis and treatment. In this report, three cases presented are discussed along with the cases in the literature.
Bookmark/Search this post with
Abstract (Original Language): 
Renal medüller karsinom böbreğin çok agresif seyirli malign epitelyal tümörüdür. Bu çalışmada biri nefrektomi, diğerleri ise biyopsiden tanı almış üç renal medüller karsinoma olgusu sunulmaktadır. Histolojik olarak tümörler, nötrofilik inflamatuvar komponentin eşlik ettiği diffüz ya da glandüler yapılardan oluşmuştu. Tümör hücreleri plazmositoid veya rabdoid görünümdedir. İmmünohistokimyasal olarak neoplastik hücrelerde epitelyal membran antijeni, vimentin, Cam 5.2, pansitokeratin (AE1/AE3) pozitifliği, fokal olarak sitokeratin 7 ve P53 pozitifliği gözlenirken, Her2neu (C-erbb2), CEA, yüksek moleküler ağırlıklı sitokeratin (34ßE12) ve sitokeratin 20 negatiftir. İki olgu tanıdan sonraki bir yıl içinde ölmüştür. Renal medüller karsinom histogenez, tanı ve tedavi yönüyle diğer böbrek karsinomlarından farklıdır. Bu yazıda sunulan üç olgu literatürdeki olgularla birlikte tartışılmaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-renal-meduller-karsinom-3-olgunun-sunumu.pdf
  • 1
53-56
  • Turkish

REFERENCES

References: 

1. Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary
carcinoma: the seventh sickle cell nephropathy. Am J Surg
Pathol 1995; 19: 1-11.
2. Noguera-Irizarry WG, Hibshoosh H, Papadopoulos KP.
Renal medullary carcinoma: case report and review of the
literature. Am J Clin Oncol 2003; 26: 489-492.
3. Davis CJ. Renal medullary carcinoma. In: Eble JN, Sauter
G, Epstein JI, Sesterhen IA (eds). World Health
Organization Classification of Tumours. Pathology and
Genetics of Tumours of the Urinary System and Male
Genital Organs. Lyon: IARC Press, 2004: 35-36.
4. Avery RE, Harris JE, Davis CJ, et al. Renal medullary carcinoma: clinical and therapeutic aspects of a newly
described tumor. Cancer 1996; 78: 128-132.
5. Patel K, Livni N, Macdonald D. Renal medullary carcinoma, a rare cause of haematuria in sickle cell trait. Br J
Haematol 2006; 132: 1.
6. Molgat G, Afrouzian M, Trpkov K. Renal medullary carcinoma as an incidental finding in a horseshoe kidney:
case report and literature review. Can J Urol 2005; 12:
2837-2840.
7. Srigley JR, Eble JN. Collecting duct carcinoma of kidney.
Semin Diagn Pathol 1998; 15: 54-67.
8. Swartz MA, Karth J, Schneider DT, et al. Renal medullary
carcinoma: clinical, pathologic, immunohistochemical,
and genetic analysis with pathogenetic implications.
Urology 2002; 60: 1083-1089.
9. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution
of cytokeratins and vimentin in adult renal neoplasms and
normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors.
Am J Surg Pathol 2005; 29: 747-754.
10. Selli C, Amorosi A, Vona G, et al. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. J
Urol 1997; 158: 245-247.
11. Jorda M, Manoharan M. Collecting duct carcinoma of
kidney. Pathol Case Rev 2006; 11: 191-196.
12. Yang XJ, Sugimura J, Tretiakova MS, et al. Gene expression profiling of renal medullary carcinoma: potential
clinical relevance. Cancer 2004; 100: 976-985.
13. Bell MD. Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma. Pediatr Blood
Cancer 2006; 47: 228.

Thank you for copying data from http://www.arastirmax.com